Federal Register Notice: FDA has determined the regulatory review period for Novartis Corp.’s Tekturna (aliskiren hemifumarate) is 2,023 days for the extension of a patent which claims that human drug product. Tekturna is indicated for treating hypertension. To view this notice, click here.
